Melatonin
For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.
Active substance: Melatonin
Examples of brand names: Circadin [EU/DE]
ATC code: N05CH01
Main use (for orientation): Sleep disorders
Documented research summary
Direct preclinical CBN/CBD–melatonin pharmacokinetic interactions with species, dose and route differences. Subjective-sleep product trial is not a pharmacokinetic assessment and shows no clear combination superiority. THC conference data: small combination cohort with external pharmacokinetic comparison data. Tumour/reproductive models do not support treatment recommendations.
Uncertainties and limitations
Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.
CBN mouse AUC and CBD human-model factors are not measured human pair factors.
16805813: endogenous biosynthesis; the substance abbreviated THC is 9-carboxy-11-nor-Delta9-THC, not Delta9-THC.
Separately recorded findings
19 separately recorded findings. Each statement applies to its documented study context.
CBN – laboratory and animal studies
Finding ID: B0284
Type of result: Direct preclinical pharmacokinetic pair assessment
Observation: Melatonin exposure approximately fourfold higher in mice.
Mechanism: Inhibition of CYP1A2-mediated melatonin metabolism
Study type: In vitro and oral mouse pharmacokinetics
Context studied: CBN inhibited CYP1A2 melatonin turnover and increased apparent oral bioavailability.
Clinical interpretation: Direct preclinical pharmacokinetic finding
Limitations and uncertainties: Not a measured human AUC factor, dosage instruction or equivalence with all CBN products.
Original sources for this finding: Preclinical Evidence for a Drug-Drug Interaction Between Cannabinol and Melatonin. [BMED39722474]
CBD – laboratory and animal studies
Finding ID: B0285
Type of result: Preclinical pharmacokinetic pair assessment and human model; not measured human pair pharmacokinetics
Observation: Dose/species-dependent melatonin pharmacokinetics; human exposure only modelled.
Mechanism: Inhibition of absorption and delayed metabolism; PEPT1/CYP1A2
Study type: Cell/microsome, mouse/rat/dog and static-model studies
Context studied: Mouse: high oral CBD 40 mg/kg reduced melatonin Cmax to 57%, AUC0.5–8h 2.85-fold. Newer paper: PEPT1 uptake inhibition in acidic conditions and time-dependent CYP1A2 inhibition; worst-case human model up to 12-fold AUC.
Clinical interpretation: No clinical human pharmacokinetic evidence
Limitations and uncertainties: Human model, not measurement; opposing effects between species. AUC time window is not total AUC; mouse doses are not clinical doses.
Original sources for this finding: LC-MS/MS-Based Concurrent Quantification of Cannabidiol and Melatonin in Mouse Plasma to Elucidate Complex PK Interactions. [BMED39771491]; Unraveling Cannabidiol's Bidirectional Regulation of Melatonin Pharmacokinetics via PEPT1/CYP1A2: Mechanistic Insights and Quantitative Projections. [BMED41599679]
CBD – clinically studied
Finding ID: B0286
Type of result: Clinical multi-substance product comparison; not pharmacokinetic assessment
Observation: No significant superiority of the low-dose combinations investigated over CBD isolate.
Mechanism: Combination product and subjective sleep; no pharmacokinetic measurement
Study type: Double-blind randomised product comparison, n=1793, 4 weeks
Context studied: Six active product arms, including melatonin 5 mg alone or with CBD 15 mg/CBN 15 mg; PROMIS sleep endpoints; 12% overall reported adverse effects, none serious.
Clinical interpretation: Limited product-specific human experience
Limitations and uncertainties: No placebo arm, separate exposure measurement or guarantee concerning rare/long-term safety. Same study, not independent pair evidence.
Original sources for this finding: The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. [BMED37162192]
CBN – clinically investigated
Finding ID: B0287
Type of result: Clinical multi-substance product comparison; not pharmacokinetic assessment
Observation: No significant superiority of the low-dose combinations investigated over CBD isolate.
Mechanism: Combination product and subjective sleep; no pharmacokinetic measurement
Study type: Double-blind randomised product comparison, n=1793, 4 weeks
Context studied: Six active product arms, including melatonin 5 mg alone or with CBD 15 mg/CBN 15 mg; PROMIS sleep endpoints; 12% overall reported adverse effects, none serious.
Clinical interpretation: Limited product-specific human experience
Limitations and uncertainties: No placebo arm, separate exposure measurement or guarantee concerning rare/long-term safety. Same study, not independent pair evidence.
Original sources for this finding: The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. [BMED37162192]
THC – clinical signals
Finding ID: B0288
Type of result: Exploratory clinical pharmacokinetic signal; historical comparison and conference abstract
Observation: Conference abstract reports higher dose-related THC Cmax and apparently faster melatonin metabolism.
Mechanism: Combination pharmacokinetics with external literature comparison
Study type: Phase I multiple-ascending-dose study, 10 actively treated Alzheimer's patients; external pharmacokinetic comparison
Context studied: THC 2.5 mg plus melatonin 1.5 mg; THC Cmax 2 ng/ml; comparison with published oral THC data.
Clinical interpretation: Preliminary conference signal
Limitations and uncertainties: No randomised THC-only control; age/formulation/study differences; gastrointestinal-transporter hypothesis not demonstrated.
Original sources for this finding: Pharmacokinetic Effects of THC and Melatonin Co‐administration in Elderly Population [BMEDPMC11713368]
CBD-containing cannabis extract – clinical signals
Finding ID: B0289
Type of result: Open-label clinical combination observation; not isolated interaction evidence
Observation: Open-label observation reported better subjective sleep/anxiety scores.
Mechanism: Combined sleep product; mechanism not isolated
Study type: 20 people, retrospective open-label, 3 months
Context studied: Melatonin 1.5 mg plus CBD 2.5 mg sublingually; no placebo control.
Clinical interpretation: Hypothesis-generating
Limitations and uncertainties: No causal interaction evidence or comparison with approved hypnotics.
Original sources for this finding: Insomnia treatment: a new multitasking natural compound based on melatonin and cannabis extracts. [BMED35147654]
CBN – laboratory and animal studies
Finding ID: B0290
Type of result: Preclinical cell-model pair assessment
Observation: Synergistic cytotoxicity reported in glioblastoma cell lines.
Mechanism: Combined tumour-cell toxicity and oxidative stress
Study type: U87/T98/U251 laboratory experiments with melatonin ± temozolomide
Context studied: High melatonin concentrations of 0.2–0.7 mg/ml; CBN/CBG in the µM range, Bliss model.
Clinical interpretation: No clinical tumour-treatment recommendation
Limitations and uncertainties: No human exposure or survival study; same paper for both cannabinoids, not an established treatment effect.
Original sources for this finding: Synergistic In Vitro Effects of Minor Phytocannabinoids and Melatonin Combinations Against Human Glioblastoma Cells. [BMED42589431]
CBG – laboratory and animal studies
Finding ID: B0291
Type of result: Preclinical cell-model pair assessment
Observation: Synergistic cytotoxicity reported in glioblastoma cell lines.
Mechanism: Combined tumour-cell toxicity and oxidative stress
Study type: U87/T98/U251 laboratory experiments with melatonin ± temozolomide
Context studied: High melatonin concentrations of 0.2–0.7 mg/ml; CBN/CBG in the µM range, Bliss model.
Clinical interpretation: No clinical tumour-treatment recommendation
Limitations and uncertainties: No human exposure or survival study; same paper for both cannabinoids, not an established treatment effect.
Original sources for this finding: Synergistic In Vitro Effects of Minor Phytocannabinoids and Melatonin Combinations Against Human Glioblastoma Cells. [BMED42589431]
CBD – laboratory and animal studies
Finding ID: B0292
Type of result: Preclinical multiple combination
Observation: Melatonin/cannabinoid/cisplatin combinations showed model-dependent synergy.
Mechanism: Multi-substance chemosensitisation in a cell model
Study type: Osteosarcoma/chondrosarcoma cell lines
Context studied: Particularly THC plus cisplatin plus melatonin; apoptosis/invasion markers.
Clinical interpretation: No clinical dose reduction
Limitations and uncertainties: Triple combination, not isolated pair pharmacokinetics; do not transfer cell-culture dose reductions to patient doses.
Original sources for this finding: A selective low-dose cisplatin strategy enabled by melatonin and cannabinoids for targeting osteosarcoma and chondrosarcoma. [BMED42362763]
THC – laboratory and animal studies
Finding ID: B0293
Type of result: Preclinical multiple combination
Observation: Melatonin/cannabinoid/cisplatin combinations showed model-dependent synergy.
Mechanism: Multi-substance chemosensitisation in a cell model
Study type: Osteosarcoma/chondrosarcoma cell lines
Context studied: Particularly THC plus cisplatin plus melatonin; apoptosis/invasion markers.
Clinical interpretation: No clinical dose reduction
Limitations and uncertainties: Triple combination, not isolated pair pharmacokinetics; do not transfer cell-culture dose reductions to patient doses.
Original sources for this finding: A selective low-dose cisplatin strategy enabled by melatonin and cannabinoids for targeting osteosarcoma and chondrosarcoma. [BMED42362763]
CBD – laboratory and animal studies
Finding ID: B0294
Type of result: Preclinical multi-substance model; not isolated pair evidence
Observation: Biological changes reported during multiple treatment; isolated melatonin/CBD contribution not determined.
Mechanism: Multi-substance tumour model with CBD, melatonin and ozone/oxygen
Study type: Pancreatic ductal adenocarcinoma cell and mouse model
Context studied: Preclinical multiple-treatment context; no human confirmation.
Clinical interpretation: No proof of isolated melatonin–CBD benefit
Limitations and uncertainties: No isolated pair causality or clinical treatment/safety conclusion.
Original sources for this finding: In Vitro and In Vivo Effects of Melatonin-Containing Combinations in Human Pancreatic Ductal Adenocarcinoma. [BMED39076059]
THC/CBD-containing cannabis products – clinical signals
Finding ID: B0295
Type of result: Clinical multiple-treatment context; no isolated pair causality
Observation: Glioblastoma single case with an unusual long-term course during cannabis/melatonin/ozone reported.
Mechanism: Non-isolated concomitant therapy
Study type: Uncontrolled single case
Context studied: Bedrocan/Bedrolite together with melatonin and other interventions.
Clinical interpretation: Not efficacy or interaction proof
Limitations and uncertainties: No reliable individual-substance causality or general cancer-treatment recommendation.
Original sources for this finding: The Effects of a Combination of Medical Cannabis, Melatonin, and Oxygen-Ozone Therapy on Glioblastoma Multiforme: A Case Report. [BMED40729189]
CBD – clinical signals
Finding ID: B0296
Type of result: Clinical multiple-treatment context; no isolated pair causality
Observation: Uncontrolled/historically compared oncology cohorts report survival.
Mechanism: Treatment context of complex neuroimmune regimens
Study type: 100 versus 212 historical patients, multiple substances
Context studied: Melatonin 100 mg, 5-methoxytryptamine, CBD or CBG for glioblastoma; comparison concerns additional angiotensin 1–7.
Clinical interpretation: No isolated pair effect
Limitations and uncertainties: Not randomised, different time cohorts; no causality of CBD/CBG plus melatonin. Same study in both rows.
Original sources for this finding: Neuroimmune treatment of advanced solid tumors: 3-year survival after angiotensin 1-7, pineal indoles, and cannabinoids. [BMED42549589]
CBG – clinical signals
Finding ID: B0297
Type of result: Clinical multiple-treatment context; no isolated pair causality
Observation: Uncontrolled/historically compared oncology cohorts report survival.
Mechanism: Treatment context of complex neuroimmune regimens
Study type: 100 versus 212 historical patients, multiple substances
Context studied: Melatonin 100 mg, 5-methoxytryptamine, CBD or CBG for glioblastoma; comparison concerns additional angiotensin 1–7.
Clinical interpretation: No isolated pair effect
Limitations and uncertainties: Not randomised, different time cohorts; no causality of CBD/CBG plus melatonin. Same study in both rows.
Original sources for this finding: Neuroimmune treatment of advanced solid tumors: 3-year survival after angiotensin 1-7, pineal indoles, and cannabinoids. [BMED42549589]
THC – laboratory and animal studies
Finding ID: B0298
Type of result: Preclinical pair assessment
Observation: Melatonin attenuated THC-induced impairment of rat sperm motility.
Mechanism: Sperm function in the laboratory
Study type: In-vitro rat sperm
Context studied: THC 1 mM, melatonin 5 mM; high concentrations.
Clinical interpretation: Not fertility treatment in humans
Limitations and uncertainties: No human finding; other cannabis-extract animal models sometimes show the opposite.
Original sources for this finding: Melatonin attenuates Δ9-tetrahydrocannabinol-induced reduction in rat sperm motility and kinematics in-vitro. [BMED29454037]
Cannabis extract, composition not standardised – laboratory and animal studies
Finding ID: B0299
Type of result: Preclinical multi-substance and pair assessments
Observation: Animal results differ: sometimes enhanced gonadal injury, sometimes improved hormones/behaviour.
Mechanism: Modulation of oxidative and reproductive endpoints
Study type: Rat experiments and one dog with behavioural training
Context studied: Melatonin plus cannabis; sometimes additional vitamin C, receptor blockers or rehabilitation.
Clinical interpretation: Not transferable to isolated THC or human therapy
Limitations and uncertainties: No uniform protective effect; species, endpoint and multiple interventions decisive.
Original sources for this finding: Melatonin and vitamin C exacerbate Cannabis sativa-induced testicular damage when administered separately but ameliorate it when combined in rats. [BMED26479341]; Cannabis sativa and/or melatonin do not alter brain lipid but alter oxidative mechanisms in female rats. [BMED34412689]; Melatonin mitigates hormonal toxicity in cannabis-treated female Wistar rats: involvement of cannabinoid receptor. [BMED41559847]; Combining cannabis and melatonin treatment with a rehabilitation program improved symptoms in a dog with compulsive disorder: A case report. [BMED37245289]
CBD – laboratory and animal studies
Finding ID: B0300
Type of result: Preclinical endogenous hormone synthesis; not an interaction with administered melatonin
Observation: Noradrenaline-induced melatonin synthesis reduced in rat pineal tissue.
Mechanism: Inhibition of endogenous melatonin biosynthesis via AANAT in the laboratory
Study type: Pineal culture/lysate
Context studied: No exogenous melatonin dose; AANAT inhibition independent of classical cannabinoid receptors.
Clinical interpretation: Endogenous mechanism, not a drug-interaction prediction
Limitations and uncertainties: Not clinical melatonin clearance or the same direction as CYP inhibition; the article's abbreviated THC metabolite is not Delta9-THC.
Original sources for this finding: Cannabinoids attenuate norepinephrine-induced melatonin biosynthesis in the rat pineal gland by reducing arylalkylamine N-acetyltransferase activity without involvement of cannabinoid receptors. [BMED16805813]
CBN – laboratory and animal studies
Finding ID: B0301
Type of result: Preclinical endogenous hormone synthesis; not an interaction with administered melatonin
Observation: Noradrenaline-induced melatonin synthesis reduced in rat pineal tissue.
Mechanism: Inhibition of endogenous melatonin biosynthesis via AANAT in the laboratory
Study type: Pineal culture/lysate
Context studied: No exogenous melatonin dose; AANAT inhibition independent of classical cannabinoid receptors.
Clinical interpretation: Endogenous mechanism, not a drug-interaction prediction
Limitations and uncertainties: Not clinical melatonin clearance or the same direction as CYP inhibition; the article's abbreviated THC metabolite is not Delta9-THC.
Original sources for this finding: Cannabinoids attenuate norepinephrine-induced melatonin biosynthesis in the rat pineal gland by reducing arylalkylamine N-acetyltransferase activity without involvement of cannabinoid receptors. [BMED16805813]
CBD – clinical signals
Finding ID: B0529
Type of result: Uncontrolled multi-substance single case; no causal pair evidence
Observation: Clinical course reported with CBD/melatonin/ozone alongside oncology treatment; no causal evidence of a CBD/melatonin pair effect.
Mechanism: Multiple concomitant therapy; isolated mechanism not determined
Study type: Uncontrolled triple-negative-breast-cancer single case
Context studied: Additional chemotherapy, radiotherapy and immunotherapy; one-person observation.
Clinical interpretation: No clinical approval
Limitations and uncertainties: Do not attribute remission to the cannabinoid/melatonin pair; not a substitute for established treatment or safety evidence.
Original sources for this finding: Integrative Use of Cannabidiol, Melatonin, and Oxygen-Ozone Therapy in Triple-Negative Breast Cancer with Lung and Mediastinal Metastases. A Case Report. [BMED41718279]
References and access status
[BFWEB_MEL] Circadin 2 mg Prolonged-release Tablets – SmPC
Original source / bibliographic reference
Authors: RAD Neurim Pharmaceuticals EEC SARL / Flynn Pharma Ltd
Year: 2021
Source type: Official UK product information/emc
Source access – 23 October 2026: Source destination was accessible when checked.
Bibliographic attribution or source identity cross-checked.
[BMED42589431] Synergistic In Vitro Effects of Minor Phytocannabinoids and Melatonin Combinations Against Human Glioblastoma Cells.
Original source / bibliographic reference
Authors: Morelli MB, Cameli G, Giangrossi M, Zeppa L, Luongo M, Amantini C, Nabissi M.
Year: 2026
Source type: Publication; title and abstract reviewed
DOI: 10.3390/ijms27156774
PMID: 42589431
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED42362763] A selective low-dose cisplatin strategy enabled by melatonin and cannabinoids for targeting osteosarcoma and chondrosarcoma.
Original source / bibliographic reference
Authors: Aydın D, Pınarbaşı AK, Aslan K, Aydın A, Canatan H.
Year: 2026
Source type: Publication; title and abstract reviewed
DOI: 10.1007/s00210-026-05551-y
PMID: 42362763
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED39722474] Preclinical Evidence for a Drug-Drug Interaction Between Cannabinol and Melatonin.
Original source / bibliographic reference
Authors: Anderson LL, Hawkins NA, Yip KL, Udoh M, Kearney JA, Arnold JC.
Year: 2025
Source type: Publication; title and abstract reviewed
DOI: 10.1111/bcpt.14120
PMID: 39722474
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED41599679] Unraveling Cannabidiol's Bidirectional Regulation of Melatonin Pharmacokinetics via PEPT1/CYP1A2: Mechanistic Insights and Quantitative Projections.
Original source / bibliographic reference
Authors: Zheng B, Wang M, Zhang Q, Li C, Wang L, Zhang W, Liu C, Zhuang X.
Year: 2025
Source type: Publication; title and abstract reviewed
DOI: 10.3390/ph19010080
PMID: 41599679
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED37162192] The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial.
Original source / bibliographic reference
Authors: Saleska JL, Bryant C, Kolobaric A, D'Adamo CR, Colwell CS, Loewy D, Chen J, Pauli EK.
Year: 2024
Source type: Publication; title and abstract reviewed
DOI: 10.1080/27697061.2023.2203221
PMID: 37162192
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED41559847] Melatonin mitigates hormonal toxicity in cannabis-treated female Wistar rats: involvement of cannabinoid receptor.
Original source / bibliographic reference
Authors: Oluwasola A.
Year: 2026
Source type: Publication; title and abstract reviewed
DOI: 10.1186/s42238-025-00375-8
PMID: 41559847
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED41718279] Integrative Use of Cannabidiol, Melatonin, and Oxygen-Ozone Therapy in Triple-Negative Breast Cancer with Lung and Mediastinal Metastases. A Case Report.
Original source / bibliographic reference
Authors: Aguzzi C, Zuccoli P, Fanelli A, Mammone A, Nabissi M, Luongo M.
Year: 2026
Source type: Publication; title and abstract reviewed
DOI: 10.3390/reports9010028
PMID: 41718279
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED42549589] Neuroimmune treatment of advanced solid tumors: 3-year survival after angiotensin 1-7, pineal indoles, and cannabinoids.
Original source / bibliographic reference
Authors: Lissoni P, Monzon A, Marroccoli S, Di Fede G, Sassola A, Messina G, Simoes-E-Silva AC, Kuznetsova IV, Burchakov DI, Kirillova MY, Cardinali DP.
Year: 2026
Source type: Publication; title and abstract reviewed
DOI: 10.4149/neo_2026_260610n190
PMID: 42549589
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED39771491] LC-MS/MS-Based Concurrent Quantification of Cannabidiol and Melatonin in Mouse Plasma to Elucidate Complex PK Interactions.
Original source / bibliographic reference
Authors: Wang M, Zhang W, Wu X, Wang L, Li C, Liu C, Zhuang X.
Year: 2024
Source type: Publication; title and abstract reviewed
DOI: 10.3390/pharmaceutics16121511
PMID: 39771491
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED39076059] In Vitro and In Vivo Effects of Melatonin-Containing Combinations in Human Pancreatic Ductal Adenocarcinoma.
Original source / bibliographic reference
Authors: Zeppa L, Aguzzi C, Morelli MB, Marinelli O, Amantini C, Giangrossi M, Santoni G, Fanelli A, Luongo M, Nabissi M.
Year: 2024
Source type: Publication; title and abstract reviewed
DOI: 10.1111/jpi.12997
PMID: 39076059
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED35147654] Insomnia treatment: a new multitasking natural compound based on melatonin and cannabis extracts.
Original source / bibliographic reference
Authors: Palmieri G, Vadalà M, Corazzari V, Palmieri B.
Year: 2022
Source type: Publication; title and abstract reviewed
DOI: 10.7417/ct.2022.2399
PMID: 35147654
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED40729189] The Effects of a Combination of Medical Cannabis, Melatonin, and Oxygen-Ozone Therapy on Glioblastoma Multiforme: A Case Report.
Original source / bibliographic reference
Authors: Antonini M, Aguzzi C, Fanelli A, Frassineti A, Zeppa L, Morelli MB, Pastore G, Nabissi M, Luongo M.
Year: 2023
Source type: Publication; title and abstract reviewed
DOI: 10.3390/reports6020022
PMID: 40729189
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED29454037] Melatonin attenuates Δ9-tetrahydrocannabinol-induced reduction in rat sperm motility and kinematics in-vitro.
Original source / bibliographic reference
Authors: Alagbonsi IA, Olayaki LA.
Year: 2018
Source type: Publication; title and abstract reviewed
DOI: 10.1016/j.reprotox.2018.02.005
PMID: 29454037
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED37245289] Combining cannabis and melatonin treatment with a rehabilitation program improved symptoms in a dog with compulsive disorder: A case report.
Original source / bibliographic reference
Authors: Sacchettino L, Gatta C, Maruccio L, Boncompagni C, Napolitano F, Avallone L, d'Angelo D.
Year: 2023
Source type: Publication; title and abstract reviewed
DOI: 10.1016/j.rvsc.2023.05.007
PMID: 37245289
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED34412689] Cannabis sativa and/or melatonin do not alter brain lipid but alter oxidative mechanisms in female rats.
Original source / bibliographic reference
Authors: Abdulrahim HA, Alagbonsi IA, Amuda O, Omeiza NA, Feyitimi AA, Olayaki LA.
Year: 2021
Source type: Publication; title and abstract reviewed
DOI: 10.1186/s42238-021-00095-9
PMID: 34412689
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED26479341] Melatonin and vitamin C exacerbate Cannabis sativa-induced testicular damage when administered separately but ameliorate it when combined in rats.
Original source / bibliographic reference
Authors: Alagbonsi IA, Olayaki LA, Salman TM.
Year: 2016
Source type: Publication; title and abstract reviewed
DOI: 10.1515/jbcpp-2015-0061
PMID: 26479341
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED16805813] Cannabinoids attenuate norepinephrine-induced melatonin biosynthesis in the rat pineal gland by reducing arylalkylamine N-acetyltransferase activity without involvement of cannabinoid receptors.
Original source / bibliographic reference
Authors: Koch M, Dehghani F, Habazettl I, Schomerus C, Korf HW.
Year: 2006
Source type: Publication; title and abstract reviewed
DOI: 10.1111/j.1471-4159.2006.03873.x
PMID: 16805813
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMEDPMC11713368] Pharmacokinetic Effects of THC and Melatonin Co‐administration in Elderly Population
Original source / bibliographic reference
Authors: Naranjo M, Camargo F, Rao J, Delgado‐Murillo L, Venegas M, Tangarife M, Arbelaez M, Gutiérrez E, Sánchez L, Shahnawaz S, Ghazaryan V, De Jesus W, Grimaldi C, Hong E, Mukunda R.
Year: 2024
Source type: Conference abstract with phase I combination data and external literature comparison
DOI: 10.1002/alz.095382
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed Central – archived text
Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.
Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility
Melatonin and cannabinoids: documented findings, evidence, sources and data gaps. Research information for discussion with your doctor or pharmacist.